Range
1.08 - 1.15
Vol / Avg.
394.9K/846.9K
Div / Yield
-
52 Wk
0.36 - 4.23
Mkt Cap
56.7M
Payout Ratio
-
Open
1.12
P/E
-
EPS
-0.29
Shares
49.7M
Outstanding
49.7M
Total Float
49.6M
Benzinga - Sep 16, 2021, 9:03AM
load more
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS
(EXPECTED)2021-11-09
REV
Q2 2021Est.ActualSurprise
EPS-0.350-0.290 0.0600
REV5.990M8.243M2.253M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Nabriva Therapeutics Questions & Anwsers

Q

How do I buy Nabriva Therapeutics (NBRV) stock?

A

You can purchase shares of Nabriva Therapeutics (NASDAQ: NBRV) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Nabriva Therapeutics's (NBRV) competitors?

A

There are no as such competitors for Nabriva Therapeutics.

Q

What is the target price for Nabriva Therapeutics (NBRV) stock?

A

The latest price target for Nabriva Therapeutics (NASDAQ: NBRV) was reported by Morgan Stanley on December 7, 2020. The analyst firm set a price target for 20.00 expecting NBRV to rise to within 12 months (a possible 1654.39% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Nabriva Therapeutics (NBRV)?

A

The stock price for Nabriva Therapeutics (NASDAQ: NBRV) is $1.14 last updated Tue Oct 26 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does Nabriva Therapeutics (NBRV) pay a dividend?

A

There are no upcoming dividends for Nabriva Therapeutics.

Q

When is Nabriva Therapeutics (NASDAQ:NBRV) reporting earnings?

A

Nabriva Therapeutics’s $Q3 earnings are confirmed for after-market on $November 9, 2021.

Q

Is Nabriva Therapeutics (NBRV) going to split?

A

There is no upcoming split for Nabriva Therapeutics.

Q

What sector and industry does Nabriva Therapeutics (NBRV) operate in?

A

Nabriva Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.